High-risk childhood acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Genetics

Background:

• Most childhood acute lymphoblastic leukemia (ALL) cases achieve remission, yet a significant subset faces relapse.
• Relapse risk stratification relies on early treatment response, host factors, and leukemic cell genetics.

Purpose of the Study:

• To review current methods for predicting ALL relapse risk.
• To discuss advancements in treating high-risk ALL, including novel agents and therapeutic strategies.

Main Methods:

• Assessing early treatment response via peripheral blast counts and bone marrow morphology.
• Determining minimal residual disease (MRD) using polymerase chain reaction (PCR) or flow cytometry.
• Analyzing genetic characteristics of leukemic cells and germline variations.

Main Results:

• Minimal residual disease (MRD) determination is the most precise measure for predicting relapse.
• Augmented therapy improves outcomes for poor responders.
• Tyrosine kinase inhibitors significantly improve outcomes for Philadelphia chromosome-positive (Ph+) ALL.
• Novel targeted agents and hybrid protocols are under investigation for specific ALL subtypes.

Conclusions:

• Early MRD assessment is crucial for guiding therapy intensification in ALL.
• Targeted therapies and novel agents show promise for high-risk and specific ALL subsets like MLL-rearranged and Ph+ ALL.
• Genome-wide studies are identifying new molecular targets for future ALL therapies.